Toxic Megacolon – A Three Case Presentation

Abstract Introduction: Toxic megacolon is a life-threatening disease and is one of the most serious complications of Clostridium difficile infection (CDI), usually needing prompt surgical intervention. Early diagnosis and adequate medical treatment are mandatory. Cases presentation: In the last two years, three Caucasian female patients have been diagnosed with toxic megacolon and treated in the Clinical Infectious Diseases Hospital, Constanta. All patients had been hospitalized for non-related conditions. The first patient was in chemotherapy for non-Hodgkin’s lymphoma, the second patient had undergone surgery for colon cancer, and the third patient had surgery for disc herniation. In all cases the toxin test (A+B) was positive and ribotype 027 was present. Abdominal CT examination, both native and after intravenous contrast, showed significant colon dilation, with marked thickening of the wall. Resolution of the condition did not occur using the standard treatment of metronidazole and oral vancomycin, therefore the therapy was altered in two cases using intracolonic administration of vancomycin and intravenous tigecycline. Conclusions: In these three cases of CDI, the risk factors for severe evolution were: concurrent malignancy, renal failure, obesity, and immune deficiencies. Ribotype 027, a marker for a virulent strain of CD, was found in all three cases complicated by toxic megacolon. The intracolonic administration of vancomycin, and intravenous tigecycline was successful when prior standard therapy had failed, and surgery was avoided.

[1]  Alexandra J. Baumann,et al.  Body mass index greater than 35 is associated with severe Clostridium difficile infection , 2017, Alimentary pharmacology & therapeutics.

[2]  B. Dezsényi,et al.  Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[3]  A. Stallmach,et al.  Clostridium-difficile-Infektion , 2016, Der Internist.

[4]  R. Aziz,et al.  Gut microbiome alterations in patients with stage 4 hepatitis C , 2016, Gut Pathogens.

[5]  L. Loo,et al.  The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series , 2016, BMC Infectious Diseases.

[6]  M. Wilcox,et al.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission , 2016, Nature Reviews Gastroenterology &Hepatology.

[7]  A. Ofosu Clostridium difficile infection: a review of current and emerging therapies , 2016, Annals of gastroenterology.

[8]  N. Khanafer,et al.  Factors predictive of severe Clostridium difficile infection depend on the definition used. , 2016, Anaerobe.

[9]  L. Valiquette,et al.  Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  B. Puri,et al.  WSES guidelines for management of Clostridium difficile infection in surgical patients , 2015, World Journal of Emergency Surgery.

[11]  A. Galecki,et al.  Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  L. Clough,et al.  Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection , 2014, Infectious Diseases and Therapy.

[13]  A. Zinsmeister,et al.  Clinical factors associated with development of severe-complicated Clostridium difficile infection. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  Linda M. Spooner,et al.  Tigecycline for the Treatment of Severe Clostridium difficile Infection , 2011, The Annals of pharmacotherapy.

[15]  Wei Xu,et al.  Intestinal Microbiota Was Assessed in Cirrhotic Patients with Hepatitis B Virus Infection , 2011, Microbial Ecology.

[16]  Na Young Kim,et al.  [A case of pseudomembranous colitis in a juvenile rheumatoid arthritis patient taking methotrexate]. , 2010, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[17]  R. Richards,et al.  Toxic megacolon associated Clostridium difficile colitis. , 2010, World journal of gastrointestinal endoscopy.

[18]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.

[19]  W. Witte,et al.  Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[20]  D. Musher,et al.  Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Yokoe,et al.  Clinical Risk Factors for Severe Clostridium difficile–associated Disease , 2009, Emerging infectious diseases.

[22]  P. Toivanen,et al.  Fecal microbiota in early rheumatoid arthritis. , 2008, The Journal of rheumatology.

[23]  D. Mercer,et al.  Fulminant Clostridium difficile colitis , 2007, Current opinion in critical care.

[24]  J. Dipersio,et al.  Severity of Clostridium difficile–Associated Disease (CDAD) in Allogeneic Stem Cell Transplant Recipients: Evaluation of a CDAD Severity Grading System , 2007, Infection Control & Hospital Epidemiology.

[25]  C. Sirio,et al.  Fulminant Clostridium difficile: An Underappreciated and Increasing Cause of Death and Complications , 2002, Annals of surgery.

[26]  L. Bodenstein,et al.  SevereClostridium difficile colitis , 1995, Diseases of the colon and rectum.

[27]  M. Orlandea,et al.  Factors Favouring the Development of Clostridium Difficile Infection in Critically Ill Patients , 2016, Journal of critical care medicine.

[28]  A. Naimushin,et al.  [Clostridium difficile-associated diarrhea: causes and relationship to reactive arthritis]. , 2011, Harefuah.

[29]  Guang-xi Li,et al.  Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .